Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in Chronic Rhinosinusitis With Nasal Polyps
NCT06516302Phase 3Completed
- Sponsor
- Zhixiang Jintai
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing GR1802 group with placebo group (2 arms). Primary endpoints: Nasal Polyps Score at 24 weeks and Nasal Congestion Score at 24 weeks. Started Sep 2024; status: completed.
02
Drugs
telikibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06516302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516302.